Product Reports Resources Pricing Login Book a demo

Ginkgo Bioworks

Biotech & Life Sciences · Boston, United States · Founded 2008 · Public via SPAC 2021

Automated cell programming and biological engineering platform.

Valuation $566M
Revenue $106M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue
Featured in
Market map US Advanced Materials Startups Jun 25, 2026 News Ayana Bio and Brevel net $1.25M BIRD grant to test illuminated fermentation for plant cell culture Jun 4, 2026 News Ginkgo reports $170M revenue, far below 2021 $1B target Mar 2, 2026 Market map Molecular farming

Investors

25 investors on Ginkgo Bioworks's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
Y Combinator
Farzad (Zod) Nazem
TSVC
Hari Raghavan
Series A 7 investors entered at this stage
Ian McNish
Felicis
Justin Kan
Vast Ventures
OS Fund
David Beyer
iGlobe Partners
Series B+ 14 investors entered at this stage
Allen & Company
Starling Ventures
General Atlantic
11.2 Capital
Baillie Gifford
Massachusetts Institute of Technology
Cascade Investment
Illumina
DARPA
Viking Global Investors
T. Rowe Price
MicroVentures
Bill Gates
Senator Investment Group

Ginkgo Bioworks mafia

Startups founded by Ginkgo Bioworks alumni

Former Ginkgo Bioworks employees who went on to start their own companies. Sorted by Dealroom signal score.

Ayana BioEst. 2021
Effendi LeonardUnited States
Signal score78
Joyn BioEst. 2018
Brynne StantonUnited States
Signal score77
Ayble HealthEst. 2020
SJSam JactelUnited States
Signal score74
Octant BioEst. 2017
Sri KosuriUnited States
Signal score68
Cypher AIEst. 2025
YYYaoyu YangUnited States
Signal score46

Book a demo to explore the full alumni network →

Global footprint

Where Ginkgo Bioworks has talent and traffic

Workforce by country
🇺🇸 United States · Boston HQ
Book a demo for the full country breakdown
Web traffic by country
5.7K monthly visits
across markets
🇺🇸 United States80.7%
🇯🇵 Japan10.5%
🇮🇳 India5.3%
🇩🇪 Germany3.5%
🇮🇹 Italy1.8%
Top 5 markets shown

Talent graph

The shape of Ginkgo Bioworks's talent

Dealroom maps Ginkgo Bioworks's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

13 standout operatorsDealroom-flagged across the org
22 AI specialistsincl. 6 core researchers
520 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Ginkgo Bioworks's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$349M patent portfolio · 252 active families

Estimated portfolio value
$349M
61.6% of market cap · 3242.7× larger than top peer Colossal ($108k)
252 active patent families
Where Ginkgo Bioworks innovates Biological organismBiotechnologyMicrobiologyMicroorganismMolecular biology

Where Ginkgo Bioworks concentrates vs peers

Each axis is a top-10 topic across Ginkgo Bioworks and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Ginkgo Bioworks's 19 investments and acquisitions.

Every disclosed deal where Ginkgo Bioworks appeared as a backer or acquirer, 2017–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

19 deals across Ginkgo Bioworks's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Ginkgo Bioworks deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Ginkgo Bioworks's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        19 of 19 deals

        Market sentiment

        What the market is saying about Ginkgo Bioworks

        An AI-synthesized read of the highest-engagement posts about Ginkgo Bioworks on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Ginkgo Bioworks on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles